Trials / Unknown
UnknownNCT04559789
Reducing Dementia Risk With Digital Health Coaching
Digital Cognitive Multidomain Alzheimer's Risk Velocity Study (DC-MARVEL)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Neurotrack Technologies, Inc. · Industry
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention. The purpose of this study is to determine the effect of a digital cognitive health program on dementia risk, cognitive function, and general health outcomes in middle age to older adults compared to a control group that receives health education.
Detailed description
Alzheimer's Disease (AD) is expected to affect 131 million people worldwide by 2050, but as many as 40% of these cases may be prevented by targeting modifiable risk factors such as diet, physical activity, cognitive engagement, and smoking. Neurotrack Technologies, Inc. will test the efficacy of a digital multi-domain lifestyle intervention with health coaching for cognitive health designed to change behaviors associated with increased risk for AD. This digital intervention addresses the challenge of scaling effective multi-domain lifestyle interventions for cognitive health and has the potential to improve risk behaviors, thereby reducing and/or delaying cognitive decline in older adults at risk for AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | MindMate + Health Coaching | The MindMate app is a digital multi-domain lifestyle intervention designed to address modifiable risk factors for dementia. The app will be augmented with digital health coaching provided by Neurotrack. |
| OTHER | Health Education | Health education materials delivered electronically |
Timeline
- Start date
- 2021-01-04
- Primary completion
- 2024-01-30
- Completion
- 2024-01-30
- First posted
- 2020-09-23
- Last updated
- 2021-08-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04559789. Inclusion in this directory is not an endorsement.